Discern - About the company
Discern is an unfunded company based in Rockville (United States). It operates as a Developer of skin biopsy tests for identifying Alzheimer disease pathology. Discern has not raised any funding yet. The company has 44 active competitors, including 18 funded and 2 that have exited. Its top competitors include companies like C₂N Diagnostics, ALZpath and NeuroDex.
Company Details
Developer of skin biopsy tests for identifying Alzheimer disease pathology. This diagnostic tool analyzes skin samples to determine the presence or absence of biological markers associated with the condition. The process involves collecting a tissue sample from a patient, which is then incubated and evaluated in a laboratory setting. Results are provided to healthcare providers to assist in clinical assessments and the management of patients experiencing cognitive decline. The procedure is intended to support diagnostic accuracy for individuals presenting with symptoms of dementia.
Key Metrics
Sign up to download Discern's company profile
Discern's funding and investors
Discern has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Discern's Competitors and alternates
Top competitors of Discern include C₂N Diagnostics, ALZpath and NeuroDex. Here is the list of Top 10 competitors of Discern, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | C₂N Diagnostics 2007, St. Louis (United States), Series B | Developer of diagnostics and therapies for Alzheimer's disease | $35M | 58/100 | |
2nd | ALZpath 2020, Carlsbad (United States), Series A | Developer of diagnostic solutions for Alzheimer's Disease | $8.41M | 55/100 | |
3rd | NeuroDex 2018, Natick (United States), Seed | Manufacturer of diagnostic tools for Alzheimer's disease | $1.36M | 54/100 | |
4th | Amydis Diagnostics 2013, San Diego (United States), Series A | Developer of diagnostics test for detection of Alzheimer's disease | $8.69M | 53/100 | |
5th | Todos Medical 2009, Rehovot (Israel), Public | Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders | - | 47/100 | |
6th | DiamiR 2009, Monmouth Junction (United States), Funding Raised | Developer of minimally invasive diagnostic tests | - | 45/100 | |
7th | ADmit Therapeutics 2017, Barcelona (Spain), Series A | Provider of diagnostic services for early detection of Alzheimer's disease | $12.9M | 42/100 | |
8th | Lucent Diagnostics 2023, Billerica (United States), Unfunded | Developer of a biomarker blood test for the diagnosis of Alzheimer's disease | - | - | 39/100 |
9th | bioLOCKEY Healthworks 2023, Bengaluru (India), Seed | Developer of point-of-care diagnostics and novel biologics by Nanobody discovery platform | $478K | 37/100 | |
10th | Veravas 2017, Oakdale (United States), Series A | Provider of platform to manage sample preparation and diagnostic solutions | $25M | 37/100 | |
59th | Discern Rockville (United States), Unfunded | Developer of skin biopsy tests for identifying Alzheimer disease pathology | - | - | - |
Looking for more details on Discern's competitors? Click here to see the top ones
Discern's Investments and acquisitions
Discern has made no investments or acquisitions yet.
Reports related to Discern
Here is the latest report on Discern's sector:
Are you a Founder ?
FAQs about Discern
Explore our recently published companies
- Domestic Drone CounterMeasures - Oregon City based, 2025 founded, Unfunded company
- RoverTech - Chervonohrad based, 2004 founded, Unfunded company
- Sensecell Data - Copenhagen based, 2017 founded, Unfunded company
- Lensing.ai ( - Mountain View based, 2020 founded, Unfunded company
- TerraPulze - Ghana based, Unfunded company
- Swarm Stage AI - United States based, Unfunded company
